Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(9), P. 1340 - 1340

Published: Aug. 30, 2023

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic approach to diverse malignancies, leading substantial enhancements in patient prognosis. However, along with their benefits, ICIs also increase incidence of immune-related adverse events (irAEs). In present paper, we highlight four cases carpal tunnel syndrome (CTS) as an uncommon manifestation toxicity induced by ICIs. Although diagnosed different patients were undergoing ICI therapy when they developed CTS-consistent side effects accompanied severe neuropathy. Prompt treatment corticosteroids, intravenous immunoglobulins, or methotrexate resulted complete symptomatic relief for all patients. This article therefore emphasizes importance recognizing and managing rare associated use ensure optimal care.

Language: Английский

---

Immunotherapy through the Lens of Non-Small Cell Lung Cancer

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 2996 - 2996

Published: May 30, 2023

Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, the discovery of CTLA-4 followed by PD-1 early 2000s led to practice-changing clinical development immune checkpoint inhibitors (ICI). Patients with lung cancer, including both small cell (SCLC) and non-small cancer (NSCLC), benefit from most commonly used form immunotherapy (ICI), resulting increased survival quality life. In NSCLC, ICIs now extended advanced NSCLC earlier stages disease, durable benefits even emergence word ‘cure’ long term responders. However, not all patients respond immunotherapy, few achieve long-term survival. may also develop immune-related toxicity, a percentage which is associated significant mortality morbidity. This review article highlights various types immunotherapeutic strategies, their modes action, trials that have widespread use focus on current challenges advancing field immunotherapy.

Language: Английский

---

The role of CD8 PET imaging in guiding cancer immunotherapy

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: July 12, 2024

Currently, immunotherapy is being widely used for treating cancers. However, the significant heterogeneity in patient responses a major challenge its successful application. CD8-positive T cells (CD8 + cells) play critical role immunotherapy. Both their infiltration and functional status tumors contribute to treatment outcomes. Therefore, accurate monitoring of CD8 cells, potential biomarker, may improve therapeutic strategy. Positron emission tomography (PET) an optimal option which can provide molecular imaging with enhanced specificity. This review summarizes mechanism action immunotherapy, highlights recent advancements PET-based tracers that visualize discusses clinical applications elucidate cancer

Language: Английский

---

RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 6, 2024

Angiogenesis, metastasis, and resistance to therapy are all facilitated by cancer-associated fibroblasts (CAFs). A CAF-based risk signature can be used predict patients' prognoses for Lung adenocarcinoma (LUAD) based on CAF characteristics. The Gene Expression Omnibus (GEO) database was gather signal-cell RNA sequencing (scRNA-seq) data this investigation. GEO TCGA databases were bulk RNA-seq microarray LUAD. scRNA-seq analyzed using the Seurat R program markers. Our goal use differential expression analysis discover differentially expressed genes (DEGs) across normal tumor samples in dataset. Pearson correlation utilized prognostic related with CAF, followed univariate Cox regression analysis. Using Lasso regression, a CAF-related created. nomogram model created clinical pathological aspects. 5 clusters identified LUAD, 4 of which associated prognosis. From 2811 DEGs, 1002 found significantly correlated clusters, led creation 8 genes. These primarily connected 41 pathways, such as antigen paocessing presentation, apoptosis, cell cycle. Meanwhile, stromal immune scores, well some cells. Multivariate revealed that an independent factor its value predicting immunotherapeutic outcomes confirmed. novel integrating stage constructed, exhibited favorable predictability reliability prognosis prediction signatures effective they may provide new strategies cancer treatments interpreting response LUAD immunotherapy.

Language: Английский

---

A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade

Pathologica, Journal Year: 2024, Volume and Issue: 116(4), P. 222 - 231

Published: Sept. 1, 2024

The uPath PD-L1 (SP263) is an AI-based platform designed to aid pathologists in identifying and quantifying positive tumor cells non-small cell lung cancer (NSCLC) samples stained with the SP263 assay.

Language: Английский

---